Special Issue

New Insights against Cancer Progression and Metastasis

Submission Deadline: 10 Dec 2022

Guest Editors

  • Portrait of Guest Editor Antonio Barbieri

    Antonio Barbieri

    S.S.D. Sperimentazione Animale, Istituto Nazionale Tumori–IRCCS–Fondazione G. Pascale, 80131 Naples, Italy

    Interests: Tumor microenvironment; Tumor metastasis; Chronic stress; Biochemistry; Genetics and molecular biology medicine immunology and microbiology

  • Portrait of Guest Editor Francesca Bruzzese

    Francesca Bruzzese

    S.S.D. Sperimentazione Animale, Istituto Nazionale Tumori–IRCCS–Fondazione G. Pascale, 80131 Naples, Italy

    Interests: In vitro and in vivo experimental anticancer strategies; Drug combination studies; Epigenetic drugs; Colon cancer; Prostate cancer; Repurposing; High-throughput and high content screening

Special Issue Information

Dear Colleagues,

Cancer metastasis is the main cause of treatment failure and mortality in cancer patients. Cancer is a complex and heterogeneous disease process involving multiple currently undiscovered mechanisms. Understanding the molecular mechanisms, particularly those involving cancer evolution, heterogeneity and metastasis, is essential to develop safe and effective treatments, as well as implementing adequate prevention measures. There are many aspects involved in cancer progression and metastasis such as epithelial mesenchimal transition (EMT), hypoxia, tyrosine kinase activaction, angiogenesis, anoikis, drug resistance, cell adhesion and invasion, apoptosis, autophagy, and cancer stem cells. Primary tumors, especially in the early stages, can be eradicated with surgery or radiotherapy, while metastases remain the leading cause of cancer death.

The differences in cellular function between primary and metastatic tumors are key determinants for the identification of the mechanisms for metastases. A targeted approach for the treatment of cancer and metastasis is mandatory to develop a rational prevention strategy.

In this Special Issue we are seeking original research articles or literature reviews to highlight the recent efforts in understanding the molecular events that give rise to cancer progression and metastasis; and the novel therapeutic strategies to fight it. We also seek contributions that highlight the combination of natural compounds, drug repurposing or dietary approaches as strategies to inhibit cancer progression and metastases. Articles describing natural compounds or synergism between two or more drugs that have beneficial effects which could be used for the treatment of cancer and metastases are also welcomed.

Dr. Antonio Barbieri and Dr. Francesca Bruzzese

Guest Editors

Keywords

  • Cancer progression
  • Metastasis
  • Signaling pathways
  • Drug repurposing
  • Targeted therapy
  • Natural compounds
  • Synergism

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. 

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted manuscripts should be well formatted in good English.

Published Papers (10)

Open Access Original Research
693
184
10
Open Access Original Research
504
143
12
Open Access Original Research
429
103
2
Open Access Original Research
1107
311
31
Open Access Review
893
538
28
Open Access Original Research
944
230
31
Open Access Review
841
224
19
Open Access Review
922
498
24
Open Access Original Research
916
282
22